Daniel Carr

List of Publications by Year
in descending order

285	17,653	31976 53	17105 122
papers	citations	h-index	g-index

302	302	302	20841
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression. Pediatric Research, 2023, 93, 97-101.	2.3	0
2	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 85-99.	3.0	23
3	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 100-103.	3.0	4
4	HLA Alleleâ€"Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. Annual Review of Pharmacology and Toxicology, 2022, 62, .	9.4	8
5	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	3.7	33
6	Roadmap to 2030 for Drug Evaluation in Older Adults. Clinical Pharmacology and Therapeutics, 2022, 112, 210-223.	4.7	19
7	Highâ€mobility group box 1 as a predictive biomarker for drugâ€resistant epilepsy: A proofâ€ofâ€concept study. Epilepsia, 2022, 63, e1.	5.1	17
8	Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. Toxicological Sciences, 2022, 186, 58-69.	3.1	13
9	Factors Affecting Patient and Physician Engagement in Remote Health Care for Heart Failure: Systematic Review. JMIR Cardio, 2022, 6, e33366.	1.7	10
10	Vitamin D, vitamin Dâ€"binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. American Journal of Clinical Nutrition, 2022, 115, 1367-1377.	4.7	12
11	Characterization of Teicoplanin-Specific T-Cells from Drug NaÃ¯ve Donors Expressing HLA-A*32:01. Chemical Research in Toxicology, 2022, 35, 199-202.	3.3	1
12	A population study of clinically actionable genetic variation affecting drug response from the Middle East. Npj Genomic Medicine, 2022, 7, 10.	3.8	20
13	Cardiovascular drugs and COVIDâ€19 clinical outcomes: a systematic review and metaâ€analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 3577-3599.	2.4	7
14	Pharmacogenomics: Relevance and opportunities for clinical pharmacology. British Journal of Clinical Pharmacology, 2022, 88, 3943-3946.	2.4	12
15	Similarity and consistency assessment of three major online drugâ€"drug interaction resources. British Journal of Clinical Pharmacology, 2022, 88, 4067-4079.	2.4	7
16	Pharmacogenomics of Drug Hypersensitivity. Immunology and Allergy Clinics of North America, 2022, 42, 335-355.	1.9	6
17	Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 249-260.	0.7	1
18	A reference set of clinically relevant adverse drug-drug interactions. Scientific Data, 2022, 9, 72.	5.3	10

#	Article	IF	Citations
19	Ethnic Diversity and Warfarin Pharmacogenomics. Frontiers in Pharmacology, 2022, 13, 866058.	3.5	17
20	Stable warfarin dose prediction in subâ€Saharan African patients: A machineâ€learning approach and external validation of a clinical doseâ€“initiation algorithm. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 20-29.	2.5	10
21	UK veterinary professionalsâ€™ perceptions and experiences of adverse drug reaction reporting. Veterinary Record, 2022, 191, .	0.3	5
22	Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology, 2021, 87, 237-255.	2.4	14
23	A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVIDâ€19 (SARSâ€CoVâ€2) treatments. British Journal of Clinical Pharmacology, 2021, 87, 707-711.	2.4	20
24	Genetic Risk Factors in Drugâ€Induced Liver Injury Due to Isoniazidâ€Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 2021, 109, 1125-1135.	4.7	31
25	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. British Journal of Clinical Pharmacology, 2021, 87, 2572-2588.	2.4	11
26	Developing and Validating a Clinical Warfarin Doseâ€Initiation Model for Blackâ€African Patients in South Africa and Uganda. Clinical Pharmacology and Therapeutics, 2021, 109, 1564-1574.	4.7	8
27	Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. , 2021, 219, 107710.		17
28	Warfarin dosing algorithms: A systematic review. British Journal of Clinical Pharmacology, 2021, 87, 1717-1729.	2.4	43
29	Beta-lactam-induced immediate hypersensitivity reactions: AÂgenome-wide association study of a deeply phenotyped cohort. Journal of Allergy and Clinical Immunology, 2021, 147, 1830-1837.e15.	2.9	26
30	Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1238-1243.	5.7	11
31	Associations between occupation and heavy alcohol consumption in UK adults aged 40â€“69â€‰years: a cross-sectional study using the UK Biobank. BMC Public Health, 2021, 21, 190.	2.9	10
32	Anticoagulation in subâ€Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. British Journal of Clinical Pharmacology, 2021, 87, 3699-3705.	2.4	12
33	Improving anticoagulation in subâ€Saharan Africa: What are the challenges and how can we overcome them?. British Journal of Clinical Pharmacology, 2021, 87, 3056-3068.	2.4	13
34	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	12.8	102
35	HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational Psychiatry, 2021, 11, 214.	4.8	12
36	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. Frontiers in Immunology, 2021, 12, 658593.	4.8	14

#	Article	IF	Citations
37	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Frontiers in Immunology, 2021, 12, 661135.	4.8	29
38	T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. , 2021, 9, e002521.		10
39	Assessing the impact of alcohol consumption on the genetic contribution to mean corpuscular volume. Human Molecular Genetics, 2021, 30, 2040-2051.	2.9	2
40	Deciphering Adverse Drug Reactions:In VitroPriming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. Toxicological Sciences, 2021, 183, 139-153.	3.1	9
41	Identification of ROBO2 as a Potential Locus Associated with Inhaled Corticosteroid Response in Childhood Asthma. Journal of Personalized Medicine, 2021, 11, 733.	2.5	6
42	Cardiovascular drugs and COVIDâ€19 clinical outcomes: A living systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 4534-4545.	2.4	16
43	HLA Class-Iâ€'Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. Journal of Investigative Dermatology, 2021, 141, 2412-2425.e2.	0.7	12
44	Probenecid Increases the Concentration of 7-Chlorokynurenic Acid Derived from the Prodrug 4-Chlorokynurenine within the Prefrontal Cortex. Molecular Pharmaceutics, 2021, 18, 113-123.	4.6	11
45	Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use. European Respiratory Journal, 2021, 57, 2003388.	6.7	17
46	Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration. EBioMedicine, 2021, 74, 103728.	6.1	5
47	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 2062-2072.	5.8	10
48	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2020, 107, 57-61.	4.7	42
49	Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. British Journal of Clinical Pharmacology, 2020, 86, 62-74.	2.4	12
50	Genetic Factors Influencing Warfarin Dose in Blackâ€African Patients: A Systematic Review and Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2020, 107, 1420-1433.	4.7	40
51	Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. Journal of Clinical Medicine, 2020, 9, 22.	2.4	122
52	Genetic variants associated with T cellâ€"mediated cutaneous adverse drug reactions: A PRISMAâ€compliant systematic reviewâ€"An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1069-1098.	5.7	16
53	Characterization of Clozapine-Responsive Human T Cells. Journal of Immunology, 2020, 205, 2375-2390.	0.8	9
54	Safety perspectives on presently considered drugs for the treatment of COVIDâ€19. British Journal of Pharmacology, 2020, 177, 4353-4374.	5.4	17

#	Article	IF	Citations
55	Pharmacogenomics for Primary Care: An Overview. Genes, 2020, 11, 1337.	2.4	30
56	Precision medicine in drug safety. Current Opinion in Toxicology, 2020, 23-24, 87-97.	5.0	2
57	Alcohol-related brain injury: An unrecognized problem in acute medicine. Alcohol, 2020, 88, 49-53.	1.7	5
58	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 2020, 30, 131-144.	1.5	26
59	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. Toxicological Sciences, 2020, 178, 115-126.	3.1	14
60	A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes, 2020, 11, 1295.	2.4	120
61	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. British Journal of Cancer, 2020, 123, 207-215.	6.4	50
62	Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. BMJ Open, 2020, 10, e033357.	1.9	17
63	Genetic Association of Coâ€Trimoxazoleâ€Induced Severe Cutaneous Adverse Reactions Is Phenotypeâ€Specific: HLA Class I Genotypes and Haplotypes. Clinical Pharmacology and Therapeutics, 2020, 108, 1078-1089.	4.7	34
64	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
65	A Genomeâ€wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clinical Pharmacology and Therapeutics, 2020, 108, 287-297.	4.7	28
66	A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific Reports, 2020, 10, 1796.	3.3	4
67	Informatics investigations into anti-thyroid drug induced agranulocytosis associated with multiple HLA-B alleles. PLoS ONE, 2020, 15, e0220754.	2.5	3
68	Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry, 2020, 10, 37.	4.8	24
69	Functional validity, role, and implications of heavy alcohol consumption genetic loci. Science Advances, 2020, 6, eaay5034.	10.3	47
70	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. Pharmacogenomics Journal, 2020, 20, 621-628.	2.0	10
71	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS ONE, 2020, 15, e0227458.	2.5	25
72	Inflammatory Bowel Disease: A Personalized Approach. Frontiers in Pediatrics, 2020, 8, 620545.	1.9	0

#	Article	IF	Citations
73	Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocrine Connections, 2020, 9, 318-325.	1.9	23
74	Pharmacogenomics in the UK National Health Service: opportunities and challenges. Pharmacogenomics, 2020, 21, 1237-1246.	1.3	15
75	Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. Scientific Reports, 2020, 10, 8394.	3.3	5
76	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
77	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
78	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
79	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
80	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
81	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
82	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS ONE, 2019, 14, e0218115.	2.5	18
83	Genetic Predisposition to Anticonvulsant Hypersensitivity. Clinical Pharmacology and Therapeutics, 2019, 106, 919-922.	4.7	2
84	Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Safety, 2019, 42, 1393-1407.	3.2	60
85	Drugâ€Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253.	4.7	58
86	Genomeâ€wide association study of inhaled corticosteroid response in admixed children with asthma. Clinical and Experimental Allergy, 2019, 49, 789-798.	2.9	50
87	Genomewide Association Study of Statinâ€Induced Myopathy in Patients Recruited Using the <scp>UK</scp> Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 2019, 106, 1353-1361.	4.7	44
88	Shared Genetic Risk Factors Across Carbamazepineâ€Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	4.7	52
89	Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. Pharmacogenomics, 2019, 20, 599-608.	1.3	4
90	HLA- and immune-mediated adverse drug reactions: Another hit with vancomycin. Journal of Allergy and Clinical Immunology, 2019, 144, 44-45.	2.9	5

#	Article	IF	Citations
91	Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC Medicine, 2019, 17, 76.	5.5	34
92	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. European Journal of Clinical Pharmacology, 2019, 75, 1135-1141.	1.9	16
93	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	1.3	97
94	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2019, 7, CD010891.	2.8	7
95	Nonmedical prescriber experiences of training and competence to report adverse drug reactions in the UK. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 78-83.	1.5	6
96	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	2.9	144
97	Costâ€Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. Clinical Pharmacology and Therapeutics, 2019, 105, 1429-1438.	4.7	25
98	Serum and blisterâ€fluid elevation and decreased epidermal content of highâ€mobility group box 1 protein in drugâ€induced Stevensâ€“Johnson syndrome/toxic epidermal necrolysis. British Journal of Dermatology, 2019, 181, 166-174.	1.5	15
99	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
100	Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 2019, 18, 41-58.	46.4	2,689
101	A Framework for Multi-Omic Prediction ofÂTreatment Response to Biologic TherapyÂfor Psoriasis. Journal of Investigative Dermatology, 2019, 139, 100-107.	0.7	30
102	Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia, 2019, 33, 1810-1814.	7.2	13
103	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-168.	0.7	0
104	Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistancein vitro. Diabetes and Vascular Disease Research, 2018, 15, 233-242.	2.0	8
105	Letter to the Editor: Response to Costa et al.. European Neuropsychopharmacology, 2018, 28, 658.	0.7	0
106	Direct oral anticoagulants versus warfarin: is new always better than the old?. Open Heart, 2018, 5, e000712.	2.3	61
107	Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity. Chemical Research in Toxicology, 2018, 31, 165-167.	3.3	16
108	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 574-581.	4.7	211

#	Article	IF	Citations
109	Nucleic acid based therapies: developing frontier for precision medicine. BMJ: British Medical Journal, 2018, 360, k223.	2.3	0
110	The prescribable drugs with efficacy in experimental epilepsies (<scp>PDE</scp>3) database for drug repurposing research in epilepsy. Epilepsia, 2018, 59, 492-501.	5.1	21
111	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	3.8	134
112	Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. Lancet Respiratory Medicine,the, 2018, 6, 442-450.	10.7	58
113	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	1.7	13
114	Identifying cisplatin-induced kidney damage in paediatric oncology patients. Pediatric Nephrology, 2018, 33, 1467-1474.	1.7	25
115	Biomarkers of adverse drug reactions. Experimental Biology and Medicine, 2018, 243, 291-299.	2.4	25
116	Renal function monitoring in heart failure â€“ what is the optimal frequency? A narrative review. British Journal of Clinical Pharmacology, 2018, 84, 5-17.	2.4	25
117	Research Directions in Genetic Predispositions to Stevensâ€“Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics, 2018, 103, 390-394.	4.7	15
118	Repurposing Statins for Renal Protection: Is It a Class Effect?. Clinical and Translational Science, 2018, 11, 100-102.	3.1	9
119	Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. The Lancet Gastroenterology and Hepatology, 2018, 3, 104-113.	8.1	99
120	Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. Molecular Pharmaceutics, 2018, 15, 3557-3572.	4.6	30
121	Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 272-281.	2.8	16
122	Warfarin: The End or the End of One Size Fits All Therapy?. Journal of Personalized Medicine, 2018, 8, 22.	2.5	26
123	TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. Journal of Hepatology, 2018, , .	3.7	4
124	Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin. Scientific Reports, 2018, 8, 5094.	3.3	16
125	Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. Critical Reviews in Oncology/Hematology, 2018, 130, 92-107.	4.4	6
126	Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions. Molecular Immunology, 2018, 101, 488-499.	2.2	14

#	Article	IF	Citations
127	Pharmacogenetics of Adverse Drug Reactions. Advances in Pharmacology, 2018, 83, 155-190.	2.0	32
128	Genetic and nongenetic factors that may predispose individuals to allergic drug reactions. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 325-332.	2.3	11
129	Adrenal suppression with inhaled corticosteroids: the seed and the soil â€“ Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e20.	10.7	1
130	Causality Patterns for Detecting Adverse Drug Reactions From Social Media: Text Mining Approach. JMIR Public Health and Surveillance, 2018, 4, e51.	2.6	29
131	Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. Journal of Clinical Lipidology, 2017, 11, 204-214.	1.5	20
132	Identifying new antiepileptic drugs through genomics-based drug repurposing. Human Molecular Genetics, 2017, 26, ddw410.	2.9	37
133	Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw545.	3.0	42
134	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
135	Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Scientific Reports, 2017, 7, 43580.	3.3	59
136	Genetic regulation of gene expression in the epileptic human hippocampus. Human Molecular Genetics, 2017, 26, 1759-1769.	2.9	20
137	HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Annals of the Rheumatic Diseases, 2017, 76, e51-e51.	0.9	11
138	A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol, 2017, 62, 11-15.	1.7	19
139	TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenetics and Genomics, 2017, 27, 213-222.	1.5	51
140	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. JAMA Dermatology, 2017, 153, 587.	4.1	30
141	Genomics of Adverse Drug Reactions. Trends in Pharmacological Sciences, 2017, 38, 100-109.	8.7	53
142	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	1.3	174
143	Open letter on access to the BIA 10-2474 clinical trial data. Lancet, The, 2017, 389, 156.	13.7	11
144	The molecular genetics of chemotherapyâ€“induced peripheral neuropathy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 127-140.	4.4	53

#	Article	IF	Citations
145	How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 219, 1-9.	1.1	13
146	Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology, 2017, 56, 1729-1739.	1.9	49
147	Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. European Neuropsychopharmacology, 2017, 27, 1077-1089.	0.7	15
148	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients. Chemical Research in Toxicology, 2017, 30, 1419-1435.	3.3	22
149	CKMGlu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	5
150	An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. Pharmacogenomics, 2017, 18, 1541-1550.	1.3	24
151	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Pharmacogenomics, 2017, 18, 931-943.	1.3	30
152	The Effect of Inhibitory Signals on the Priming of Drug Haptenâ€“Specific T Cells That Express Distinct Vβ2 Receptors. Journal of Immunology, 2017, 199, 1223-1237.	0.8	41
153	Aminoglycoside-induced nephrotoxicity in children. Pediatric Nephrology, 2017, 32, 2015-2025.	1.7	97
154	New Approaches to Investigate Drug-Induced Hypersensitivity. Chemical Research in Toxicology, 2017, 30, 239-259.	3.3	18
155	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	6.4	24
156	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	2.2	41
157	The HLA-A*31:01 allele: influence on carbamazepine treatment. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 29-38.	0.7	31
158	Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool. PLoS ONE, 2017, 12, e0169393.	2.5	26
159	Epidemiology of alcohol dependence in UK primary care: Results from a large observational study using the Clinical Practice Research Datalink. PLoS ONE, 2017, 12, e0174818.	2.5	10
160	Development of ELISAs for diagnosis of acute typhoid fever in Nigerian children. PLoS Neglected Tropical Diseases, 2017, 11, e0005679.	3.0	16
161	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2017, 127, 2118-2132.	8.2	90
162	Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study. PLoS ONE, 2017, 12, e0173272.	2.5	28

#	Article	IF	Citations
163	Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516Gâ†'T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 2016, 60, 4511-4518.	3.2	18
164	Detection of Drug-Induced Acute Kidney Injury in Humans Using Urinary KIM-1, miR-21, -200c, and -423. Toxicological Sciences, 2016, 152, 205-213.	3.1	58
165	A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. Alcohol and Alcoholism, 2016, 51, 584-592.	1.6	3
166	Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. Toxicological Sciences, 2016, 154, 416-429.	3.1	40
167	An integrative in silico system for predicting dysregulated genes in the human epileptic focus: Application to <scp>SLC</scp> transporters. Epilepsia, 2016, 57, 1467-1474.	5.1	4
168	Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. Journal of NeuroVirology, 2016, 22, 852-860.	2.1	48
169	CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine, 2016, 83, 139-146.	3.2	22
170	Precision Dosing in Children. Expert Review of Precision Medicine and Drug Development, 2016, 1, 69-78.	0.7	18
171	Advances in the Pharmacogenomics of Adverse Drug Reactions. Drug Safety, 2016, 39, 15-27.	3.2	29
172	A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. Pharmacoeconomics, 2016, 34, 771-793.	3.3	111
173	Achieving the World Health Organization's vision for clinical pharmacology. British Journal of Clinical Pharmacology, 2016, 81, 223-227.	2.4	13
174	A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Medicine, 2016, 8, 2.	8.2	41
175	Childhood asthma exacerbations and the Arg16 Î²2-receptor polymorphism: AÂmeta-analysis stratified by treatment. Journal of Allergy and Clinical Immunology, 2016, 138, 107-113.e5.	2.9	80
176	Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. PLoS ONE, 2016, 11, e0165567.	2.5	16
177	Social media and pharmacovigilance: A review of the opportunities and challenges. British Journal of Clinical Pharmacology, 2015, 80, 910-920.	2.4	103
178	A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. International Journal of Pharmacy Practice, 2015, 23, 447-455.	0.6	10
179	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. Scientific Reports, 2015, 5, 13306.	3.3	6
180	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open, 2015, 5, e009566.	1.9	9

#	Article	IF	Citations
181	Monocyte unresponsiveness and impaired IL1Î², TNFÎ± and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis. BMC Infectious Diseases, 2015, 15, 513.	2.9	14
182	Characterization of amoxicillinâ€•and clavulanic acidâ€specific T cells in patients with amoxicillinâ€clavulanateâ€“induced liver injury. Hepatology, 2015, 62, 887-899.	7.3	83
183	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. British Journal of Clinical Pharmacology, 2015, 80, 1149-1159.	2.4	28
184	HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity. Pharmacogenetics and Genomics, 2015, 25, 186-198.	1.5	26
185	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thrombosis Research, 2015, 136, 69-75.	1.7	28
186	Oral anticoagulation: a critique of recent advances and controversies. Trends in Pharmacological Sciences, 2015, 36, 153-163.	8.7	70
187	Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 221-241.	6.6	57
188	Promiscuous T-cell responses to drugs and drug-haptens. Journal of Allergy and Clinical Immunology, 2015, 136, 474-476.e8.	2.9	41
189	Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. Journal of Oncology Pharmacy Practice, 2015, 21, 220-223.	0.9	10
190	In Vitro Priming of NaÄ±Ìˆve T-cells with p-Phenylenediamine and Bandrowskiâ€™s Base. Chemical Research in Toxicology, 2015, 28, 2069-2077.	3.3	16
191	Costâ€effectiveness of screening for <scp>HLA</scp>â€<scp>A</scp>*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia, 2015, 56, 556-563.	5.1	59
192	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. Pharmacogenomics, 2015, 16, 919-928.	1.3	14
193	Development of interferon beta-neutralising antibodies in multiple sclerosisâ€”a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2015, 71, 1287-1298.	1.9	17
194	Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. Human Molecular Genetics, 2015, 24, 4306-4316.	2.9	45
195	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. Journal of Allergy and Clinical Immunology, 2015, 136, 236-244.	2.9	80
196	Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics, 2015, 16, 1253-1263.	1.3	29
197	Adrenal responses to a lowâ€dose short synacthen test in children with asthma. Clinical Endocrinology, 2015, 82, 648-656.	2.4	24
198	Pharmacogenetics of Adverse Drug Reactions. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-156.	0.6	0

#	Article	IF	Citations
199	Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study. PLoS ONE, 2014, 9, e106118.	2.5	39
200	Pharmacogenomics: Current State-of-the-Art. Genes, 2014, 5, 430-443.	2.4	50
201	CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. Journal of Antimicrobial Chemotherapy, 2014, 69, 3329-3334.	3.0	36
202	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 2014, 5, 4757.	12.8	153
203	Phenotype Standardization for Statin-Induced Myotoxicity. Clinical Pharmacology and Therapeutics, 2014, 96, 470-476.	4.7	166
204	Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?. Pharmacogenomics, 2014, 15, 897-900.	1.3	1
205	Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. British Journal of Clinical Pharmacology, 2014, 78, 649-659.	2.4	27
206	Electronic health records for biological sample collection: feasibility study of statinâ€induced myopathy using the <scp>C</scp>linical <scp>P</scp>ractice <scp>R</scp>esearch <scp>D</scp>atalink. British Journal of Clinical Pharmacology, 2014, 77, 831-838.	2.4	11
207	Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. Antimicrobial Agents and Chemotherapy, 2014, 58, 706-712.	3.2	24
208	Is the Interleukin 8 Promoter Polymorphism rs4073/-251T >A Associated With Clostridium difficile Infection?. Clinical Infectious Diseases, 2014, 58, e148-e151.	5.8	6
209	Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. Drug Discovery Today, 2014, 19, 361-366.	6.4	8
210	Treatment of paracetamol overdose: room for improvement?. Lancet, The, 2014, 383, 672-674.	13.7	10
211	Editorial Commentary: Statins, Immunomodulation, and Infections: A Complex and Unresolved Relationship. Clinical Infectious Diseases, 2014, 58, 357-358.	5.8	3
212	Validation of a multigenic model to predict seizure control in newly treated epilepsy. Epilepsy Research, 2014, 108, 1797-1805.	1.6	15
213	Serum Mannose-Binding Lectin Concentration, but Not Genotype, Is Associated With Clostridium difficile Infection Recurrence: A Prospective Cohort Study. Clinical Infectious Diseases, 2014, 59, 1429-1436.	5.8	15
214	Identification of susceptible HLA class II coâ€amoxiclav genotypes based on the analysis of drugâ€specific Tâ€cells from patients with liver injury. Clinical and Translational Allergy, 2014, 4, O3.	3.2	2
215	Characterization of amoxicillin and clavulanicâ€acidâ€responsive CD4+ And CD8+ Tâ€cells in patients with coâ€amoxiclavâ€induced liver injury. Clinical and Translational Allergy, 2014, 4, P42.	3.2	0
216	Genomeâ€wide association study of nevirapine hypersensitivity in a malawian HIVâ€infected population. Clinical and Translational Allergy, 2014, 4, P125.	3.2	0

#	Article	IF	Citations
217	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. Annual Review of Genomics and Human Genetics, 2014, 15, 349-370.	6.2	128
218	A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction. PLoS ONE, 2014, 9, e114896.	2.5	12
219	The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Health Technology Assessment, 2014, 18, 1-146.	2.8	114
220	Folate Augmentation of Treatment â€“ Evaluation for Depression (FolATED): randomised trial and economic evaluation. Health Technology Assessment, 2014, 18, 1-160.	2.8	28
221	ADRIC: Adverse Drug Reactions In Children â€“ a programme of research using mixed methods. Programme Grants for Applied Research, 2014, 2, 1-184.	1.0	17
222	SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 2013, 94, 695-701.	4.7	124
223	A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 2013, 369, 2294-2303.	27.0	735
224	CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood, 2013, 122, 4253-4258.	1.4	35
225	Pharmacogenetic tests: the need for a level playing field. Nature Reviews Drug Discovery, 2013, 12, 3-4.	46.4	39
226	CYP2C19*17 Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. Clinical Pharmacology and Therapeutics, 2013, 93, 195-203.	4.7	30
227	Institutional Profile: The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK. Pharmacogenomics, 2013, 14, 861-867.	1.3	0
228	Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. Clinical Infectious Diseases, 2013, 56, 1330-1339.	5.8	100
229	The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. European Heart Journal, 2013, 34, 1958-1963.	2.2	23
230	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2013, , .	2.8	6
231	Genetics and the Potential for Predictive Tests in Adverse Drug Reactions. Chemical Immunology and Allergy, 2012, 97, 18-31.	1.7	42
232	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 2012, 22, 10-19.	1.5	38
233	An Investigation of Disagreement in Causality Assessment of Adverse Drug Reactions. Pharmaceutical Medicine, 2011, 25, 17-24.	1.9	10
234	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	1.3	412

#	Article	IF	Citations
235	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	27.0	815
236	Pharmacogenetics: past, present and future. Drug Discovery Today, 2011, 16, 852-861.	6.4	80
237	The IL1RN Promoter rs4251961 Correlates with IL-1 Receptor Antagonist Concentrations in Human Infection and Is Differentially Regulated by GATA-1. Journal of Immunology, 2011, 186, 2329-2335.	0.8	35
238	Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wiener Klinische Wochenschrift, 2010, 122, 62-64.	1.9	20
239	Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. Journal of Antimicrobial Chemotherapy, 2010, 65, 1889-1893.	3.0	40
240	Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries. Drug Metabolism and Disposition, 2010, 38, 122-132.	3.3	55
241	Pharmacogenetics of Idiosyncratic Adverse Drug Reactions. Handbook of Experimental Pharmacology, 2010, , 477-491.	1.8	28
242	The applications of pharmacogenetics to prescribing: what is currently practicable?. Clinical Medicine, 2009, 9, 493-495.	1.9	7
243	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics, 2009, 41, 816-819.	21.4	950
244	Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics Journal, 2009, 9, 291-305.	2.0	37
245	Clinical management of HIV-associated lipodystrophy. Current Opinion in Lipidology, 2009, 20, 309-314.	2.7	8
246	Adverse drug reactions and pharmacogenomics: recent advances. Personalized Medicine, 2008, 5, 11-23.	1.5	21
247	Drug hypersensitivity reactions in patients with HIV disease. Expert Review of Clinical Immunology, 2007, 3, 395-410.	3.0	5
248	Investigation into the multidimensional genetic basis of drug-induced Stevensâ€“Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 2007, 8, 1661-1691.	1.3	33
249	Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenetics and Genomics, 2007, 17, 1091-1100.	1.5	37
250	Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenetics and Genomics, 2007, 17, 961-972.	1.5	30
251	An association study of common SNPs in SREBPâ€2 and SCAP genes with simvastatin response in Saudi patients. FASEB Journal, 2007, 21, A182.	0.5	2
252	Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.. Blood, 2007, 110, 2364-2364.	1.4	2

#	Article	IF	Citations
253	Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS Journal, 2006, 8, E20-E26.	4.4	84
254	Warfarin: almost 60 years old and still causing problems. British Journal of Clinical Pharmacology, 2006, 62, 509-511.	2.4	283
255	Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis. Antiviral Therapy, 2006, 11, 393-5.	1.0	3
256	Drug-Specific T Cells in An HIV-Positive Patient with Nevirapine-Induced Hepatitis. Antiviral Therapy, 2006, 11, 393-395.	1.0	12
257	Anticipating, investigating and managing the adverse effects of drugs. Clinical Medicine, 2005, 5, 23-26.	1.9	8
258	Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy, 2005, 10, 207-213.	1.0	40
259	Drugs and the retina. Expert Opinion on Drug Safety, 2004, 3, 249-259.	2.4	16
260	Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ: British Medical Journal, 2004, 329, 15-19.	2.3	2,430
261	Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics and Genomics, 2004, 14, 335-342.	5.7	274
262	Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-Î± and Tnf-Receptor Levels, and on Metabolic Parameters. Antiviral Therapy, 2004, 9, 879-887.	1.0	6
263	Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology, 2003, 192, 23-32.	4.2	132
264	Adverse drug reactions: back to the future. British Journal of Clinical Pharmacology, 2003, 55, 486-492.	2.4	63
265	Intracellular Disposition and Metabolic Effects of Zidovudine, Stavudine and Four Protease Inhibitors in Cultured Adipocytes. Antiviral Therapy, 2003, 8, 417-426.	1.0	42
266	Understanding drug interactions. Nursing and Residential Care, 2002, 4, 312-317.	0.1	1
267	The danger hypothesisâ€"potential role in idiosyncratic drug reactions. Toxicology, 2002, 181-182, 55-63.	4.2	133
268	Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. British Journal of Clinical Pharmacology, 2001, 51, 81-86.	2.4	134
269	Carbamazepine is not a substrate for P-glycoprotein. British Journal of Clinical Pharmacology, 2001, 51, 345-349.	2.4	123
270	Pharmacogenetics and pharmacogenomics. British Journal of Clinical Pharmacology, 2001, 52, 345-347.	2.4	128

#	Article	IF	Citations
271	Drug metabolism and drug toxicity. Inflammopharmacology, 2001, 9, 183-199.	3.9	3
272	Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. British Journal of Pharmacology, 2001, 133, 295-305.	5.4	115
273	Hepatocellular response to chemical stress in CD-1 mice: Induction of early genes andÎ³-glutamylcysteine synthetase. Hepatology, 2000, 32, 321-333.	7.3	55
274	Plasma Cysteine Deficiency and Decreased Reduction of Nitrososulfamethoxazole with HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1929-1938.	1.1	62
275	Immunological Principles of Adverse Drug Reactions. Drug Safety, 2000, 23, 483-507.	3.2	127
276	Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. British Journal of Pharmacology, 1999, 126, 1393-1407.	5.4	126
277	The adverse effects of drugs. British Journal of Hospital Medicine, 1999, 60, 348-352.	0.2	10
278	Safety assessment of peroxide antimalarials: clinical and chemical perspectives. British Journal of Clinical Pharmacology, 1998, 46, 521-529.	2.4	41
279	Mechanism of Clozapine-Induced Agranulocytosis. CNS Drugs, 1997, 7, 139-158.	5.9	82
280	Idiosyncratic Drug Reactions. Clinical Pharmacokinetics, 1996, 31, 215-230.	3.5	81
281	Lack of association between schizophrenia and theCYPZD6 gene polymorphisms. American Journal of Medical Genetics Part A, 1996, 67, 236-237.	2.4	14
282	The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. British Journal of Clinical Pharmacology, 1996, 42, 347-353.	2.4	34
283	The Role of Active Metabolites in Drug Toxicity. Drug Safety, 1994, 11, 114-144.	3.2	69
284	Metabolic Mechanisms. , 0, , 57-75.		0
285	Mechanisms of Adverse Drug Reactions. , 0, , 85-103.		3